Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On August 29,2022

 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2022 ,inter alia, to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, August 29,2022, inter alia, to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30, 2022 and to consider recommendation of dividend (if any).
05-08-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 We have been informed by our Registrars and Share Transfer Agents (RTA), KFin Technologies Limited on August 03,2022, regarding the loss /misplacement of the share certificate(s). We request you to take the same on record and acknowledge receipt.
03-08-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Certificate Under Regulation 40(9) Of The SEBI Listing Regulations.

 With reference to the above we are enclosing herewith Certificate under Regulation 40(9) of the SEBI Listing Regulations for the year ended June 30, 2022. Kindly acknowledge receipt
29-07-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Compliance Certificate As Per Reg. 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended June 30,2022

 With reference to the above we are enclosing herewith compliance certificate as per Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Financial Year ended June 30,2022. Kindly acknowledge receipt.
19-07-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 With reference to above captioned subject, on the basis of confirmation received from our Registrar and Transfer Agent, Kfin Technologies Limited ( formerly known as Kfin Technologies Private Limited), we confirm that the details of securities dematerialised during the quarter ended June 30,2022 as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, have been furnished to the stock exchanges where the shares of the Company are listed within the prescribed time period. We enclose herewith the copy of letter received from Kfin Technologies Limited confirming the above. Kindly acknowledge receipt.
15-07-2022

Going off-patent, key diabetes drug likely to get 50-70% cheaper

 Merck's Sitagliptin set to lose patent this month; around 200 brands from 50 firms may enter the market
08-07-2022

Merck in advanced talks to buy Seagen in nearly $40-bn deal: Report

 Seagen has several clinical-stage oncology candidates, as well as four approved drugs including breast cancer therapy Tukysa
07-07-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyProcter & Gamble Health Ltd 2CIN NO.L99999MH1967PLC013726 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Zeal Shah Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Amit Gupta Designation: Director and Chief Financial Officer EmailId: [email protected] Date: 07/07/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
07-07-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Closure of Trading Window

 We would like to inform you that the Trading Window of the Company shall remain closed for Directors and designated employees from July 1, 2022 until 48 hours from the publication of the audited financial results for quarter and Financial Year ended June 30, 2022. Kindly take the same on record.
28-06-2022
Bigul

Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company, on June 17,2022. We request you to take the same on record and acknowledge the receipt.
21-06-2022
Next Page
Close

Let's Open Free Demat Account